Radiation Oncology

Diffuse Parenchymal Lung Disease

Questions discussed in this category

Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?

1 Answer available

How does the presence of interstitial lung disease affect your decision to offer SBRT for early stage NSCLC?

Specifically in O2-dependent patients? Have any dose/fractionation regimens been shown to reduce the risk of pneumonitis in this population?

6 Answers available

Papers discussed in this category

Clin Lung Cancer, 2017 Jul 10

Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT).

J Thorac Oncol,

Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer.

Clinical lung cancer, 2018-07

Fatal Radiation Pneumonitis in Patients With Subclinical Interstitial Lung Disease.

Int. J. Radiat. Oncol. Biol. Phys., 2017 Mar 15

Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016-06

Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).

Journal of vascular and interventional radiology : JVIR, 2021 Mar 31

Effectiveness of Thermal Ablation and Stereotactic Radiotherapy Based on Stage I Lung Cancer Histology.

International journal of radiation oncology, biology, physics, 2023 Mar 07

Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis.

Related Topics in Radiation Oncology